Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jarkko Haapasaari

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
The Journal of Rheumatology|November 5, 2002
Hepatotoxicity in patients with juvenile idiopathic arthritis receiving longterm methotrexate therapyPekka Lahdenne, Juhani Rapola, Heikki Ylijoki, et al.
Arthritis and Rheumatism|May 10, 2005
Hydroxychloroquine does not decrease serum methotrexate concentrations in children with juvenile idiopathic arthritisJarkko Haapasaari, Hannu Kautiainen, Heikki Isomäki, et al.
The Journal of Rheumatology|November 2, 2004
Etanercept does not essentially increase the total costs of the treatment of refractory juvenile idiopathic arthritisJarkko Haapasaari, Hannu J Kautiainen, Heikki A Isomäki, et al.
The Journal of Rheumatology|July 2, 2004
Growth hormone is effective in the treatment of severe growth retardation in children with juvenile chronic arthritis. Double blind placebo-controlled followup studyMarja-Terttu Saha, Jarkko Haapasaari, Sirpa Hannula, et al.
The Journal of Rheumatology|June 8, 2006
Functioning and preferences for improvement of health among patients with juvenile idiopathic arthritis in early adulthood using the WHO ICF modelMarja Arkela-Kautiainen, Jarkko Haapasaari, Hannu Kautiainen, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
The Journal of Rheumatology|November 5, 2002
Hepatotoxicity in patients with juvenile idiopathic arthritis receiving longterm methotrexate therapyPekka Lahdenne, Juhani Rapola, Heikki Ylijoki, et al.
Arthritis and Rheumatism|May 10, 2005
Hydroxychloroquine does not decrease serum methotrexate concentrations in children with juvenile idiopathic arthritisJarkko Haapasaari, Hannu Kautiainen, Heikki Isomäki, et al.
The Journal of Rheumatology|November 2, 2004
Etanercept does not essentially increase the total costs of the treatment of refractory juvenile idiopathic arthritisJarkko Haapasaari, Hannu J Kautiainen, Heikki A Isomäki, et al.
The Journal of Rheumatology|July 2, 2004
Growth hormone is effective in the treatment of severe growth retardation in children with juvenile chronic arthritis. Double blind placebo-controlled followup studyMarja-Terttu Saha, Jarkko Haapasaari, Sirpa Hannula, et al.
The Journal of Rheumatology|June 8, 2006
Functioning and preferences for improvement of health among patients with juvenile idiopathic arthritis in early adulthood using the WHO ICF modelMarja Arkela-Kautiainen, Jarkko Haapasaari, Hannu Kautiainen, et al.
Pageof 1